Compounding HRT Solutions for Weight Management Hormone Support Patients

According to NIH MedlinePlus and the Endocrine Society Clinical Practice Guideline, in individuals experiencing hormonal shifts associated with perimenopause and menopause, unexplained weight gain may present as a gradual increase in body mass despite no significant change in diet or activity level. Changes may manifest as added adipose tissue around the abdomen, hips, or thighs, a rising BMI, and subjective reports of tighter clothing. NIH MedlinePlus notes that water retention, bloating, reduced muscle tone, and shifts in appetite or energy are commonly associated with these hormonal transitions; changes may develop over weeks to months and may appear disproportionate to minor lifestyle variations. Patients experiencing persistent or significant unexplained weight changes should seek evaluation from a qualified clinician; sudden or severe symptoms — such as rapid unintentional weight gain accompanied by swelling, shortness of breath, or cardiac symptoms — may indicate a serious underlying condition and require urgent medical attention.

According to NAMS (The Menopause Society) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in individuals undergoing menopausal transition, increased abdominal fat may reflect changes in estrogen levels that influence fat distribution, shifting adipose deposition toward the visceral and central regions. The Endocrine Society Clinical Practice Guideline notes that central adiposity is commonly associated with changes in metabolic risk markers, including insulin sensitivity and lipid profiles. Patients noticing a significant or rapid increase in abdominal girth should seek evaluation from a qualified clinician; in some cases, central adiposity may indicate underlying metabolic or endocrine conditions requiring medical assessment.

According to the Endocrine Society Clinical Practice Guideline and NIH MedlinePlus, difficulty losing weight despite adherence to diet and exercise may reflect underlying hormonal imbalance, including changes in metabolic rate, altered fat distribution, and insulin resistance commonly associated with perimenopause and menopause. According to NAMS (The Menopause Society), these physiological changes may contribute to repeated weight-loss plateaus, gradual increases in waist circumference, and persistence of stubborn fat around the abdomen and hips. Additionally, low energy, sleep disruption, mood changes, and intensified hunger or cravings despite caloric control are commonly reported during this transition. Patients experiencing these concerns should seek evaluation from a qualified clinician; sudden or severe metabolic symptoms — such as extreme fatigue, confusion, or marked changes in blood sugar levels — may indicate a serious underlying condition and require urgent medical attention.

According to NIH MedlinePlus and the Endocrine Society Clinical Practice Guideline, persistent sugar and carbohydrate cravings may present as a near-constant, intense urge to consume sweets or starchy foods, frequently accompanied by difficulty resisting and repeated snacking episodes. These cravings are commonly associated with hormonal factors such as insulin resistance, fluctuating levels of estrogen and progesterone, and altered appetite-regulating hormones including leptin and ghrelin, as described in the American Diabetes Association Standards of Medical Care. According to NIDDK, cravings may be accompanied by energy dips and mood shifts, particularly in the afternoon or evening. Patients experiencing severe or disruptive cravings alongside other metabolic symptoms should seek evaluation from a qualified clinician; symptoms such as intense hunger accompanied by tremor, confusion, or diaphoresis may indicate hypoglycemia or another urgent condition requiring prompt medical attention.

According to the FDA-approved prescribing information for Semaglutide, Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbid condition, and also indicated for the treatment of type 2 diabetes mellitus. The labeling describes that Semaglutide acts on GLP-1 receptors in the brain to reduce appetite and food intake and slows gastric emptying, contributing to reduced caloric consumption. Per the labeling, Semaglutide may cause nausea, vomiting, diarrhea, and other gastrointestinal effects; it may also increase heart rate and the labeling includes a boxed warning regarding the risk of thyroid C-cell tumors observed in rodent studies, with unknown relevance to humans. Any compounded preparation involving Semaglutide is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available Semaglutide products are separately regulated, and clinical decisions about their use belong with the prescribing clinician.

According to the FDA-approved prescribing information for Phentermine, Phentermine is a sympathomimetic amine anorectic agent indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification, and caloric restriction for the management of exogenous obesity in patients with an initial body mass index of 30 kg/m² or higher, or 27 kg/m² or higher in the presence of other risk factors. The labeling describes that Phentermine acts on central noradrenergic pathways to suppress appetite, facilitating a caloric deficit. Per the labeling, Phentermine may cause increased heart rate and blood pressure, insomnia, dry mouth, and other stimulant-related effects; it may also carry a risk of dependence and is classified as a Schedule IV controlled substance. The labeling notes that primary pulmonary hypertension and serious valvular heart disease have been reported in patients taking anorectic agents, and the drug is contraindicated in patients with cardiovascular disease, hyperthyroidism, glaucoma, and certain other conditions. According to the Endocrine Society Clinical Practice Guideline, use of prescription weight-management medications should be part of a comprehensive, clinician-supervised treatment program. Any compounded preparation involving Phentermine is not reviewed by FDA for safety or effectiveness before dispensing. Commercially available Phentermine products are separately regulated, and clinical decisions about their use belong with the prescribing clinician.